Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
RESTOR: PK/PD mTORi Inhibition in Older Adults
- Conditions
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 194
- Registration Number
- NCT06658093
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06584773
- Locations
- 🇧🇷
Renal Transplantation Service, Sao Paulo, Brazil
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 260
- Registration Number
- NCT06561022
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06482086
- Locations
- 🇨🇳
West China hospital, Chengdu, Sichuan, China
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06428396
- Locations
- 🇨🇱
Centro de Investigación del Maule ( Site 4106), Talca, Maule, Chile
🇺🇸Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia, United States
🇺🇸CHRISTUS Highland ( Site 0005), Shreveport, Louisiana, United States
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 240
- Registration Number
- NCT06382948
- Locations
- 🇪🇸
Hospital Universitario Doce de Octubre, Madrid, Spain
🇪🇸Hospital Arnau de Vilanova de Valencia, Valencia, Spain
🇬🇧Barts Health NHS Trust, London, United Kingdom
Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT06301386
- Locations
- 🇨🇳
Anyang Tumor Hospital, Anyang, Henan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 340
- Registration Number
- NCT06280950
- Locations
- 🇺🇸
Mayo Clinic Hospital Arizona (Site #: 71144), Phoenix, Arizona, United States
🇺🇸University of California, San Francisco (Site #: 71108), San Francisco, California, United States
🇺🇸Northwestern University (Site #: 71110), Chicago, Illinois, United States
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 28
- Registration Number
- NCT06126588
- Locations
- 🇫🇷
CHRU of Nancy, Vandœuvre-lès-Nancy, Grand Est, France
🇫🇷Nancy Hospital, Vandœuvre-lès-Nancy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.